{"DataElement":{"publicId":"3143294","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Progesterone Receptor Status Result Score","preferredDefinition":"the result of an Oncotype DX breast cancer progesterone receptor assay, a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early-stage breast cancer.","longName":"LAB_ONCODX_PR_RSL_SC","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3143275","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Progesterone Receptor Status Result","preferredDefinition":"information relating to the result of a medical procedure that involves testing a tissue sample by the Oncotype DX breast cancer assay (a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early-stage breast cancer) and progesterone receptor status (the progesterone receptor level measured in a primary tumor or in metastases).","longName":"LAB_ONCODX_PR_RSLT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3143273","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Progesterone Receptor Status Outcome","preferredDefinition":"Oncotype DX is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen. (from genomichealth.com):Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards):Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C52159:C16149:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9143A39E-2880-5F4D-E040-BB89AD434F70","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-27","modifiedBy":"ONEDATA","dateModified":"2010-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9143A39E-2891-5F4D-E040-BB89AD434F70","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-27","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3143289","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Receptor Score","preferredDefinition":"the Oncotype DX breast cancer receptor score.","longName":"ONCOTPDX_RECEPTOR_SC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"1","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2193207","version":"1","preferredName":"Score","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"EACFDBFA-EFD4-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9143C568-37C7-5E10-E040-BB89AD4302A3","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-27","modifiedBy":"ONEDATA","dateModified":"2010-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280815","version":"1","longName":"NWU2015-06-04","context":"DCP"}]}],"AlternateNames":[{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"Oncotype DX PR Score","type":"Preferred Question Text","description":"Oncotype DX PR Score","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9143C568-382E-5E10-E040-BB89AD4302A3","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-27","modifiedBy":"TITARENKOI","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}